Trial reportProceedings of the National Academy of Sciences of the United States of America1990
Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex.
Trial report in Proceedings of the National Academy of Sciences of the United States of America, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 75 citations in OpenAlex.
- Can repeated plasma donation by asymptomatic HIV-infected individuals delay the onset of AIDS?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 1997Trial
- Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma.Proceedings of the National Academy of Sciences of the United States of America · 1995Trial
- Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.Journal of clinical immunology · 1992Trial
- Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review.AIDS research and therapy · 2025Review
- Therapeutic potential of HIV-1 entry inhibitor peptidomimetics.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1.Cell host & microbe · 2017Review
- Broadly Neutralizing Antibodies for HIV Eradication.Current HIV/AIDS reports · 2016Review
- Back to the future: antibody-based strategies for the treatment of infectious diseases.Molecular biotechnology · 2002Review
- Immunity to retroviral infection: the Friend virus model.Proceedings of the National Academy of Sciences of the United States of America · 1997Review
- Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.Proceedings of the National Academy of Sciences of the United States of America · 1995Article
- Passive antibody protection of cats against feline immunodeficiency virus infection.Journal of virology · 1993Article
- Pathogenesis of human immunodeficiency virus infection.Microbiological reviews · 1993Review
- Molecular biology made easy. The polymerase chain reaction.The Histochemical journal · 1992Review
- B cell responses to HIV and the development of human monoclonal antibodies.Clinical and experimental immunology · 1992Review
- Human immunodeficiency virus (HIV) Tat-reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope.The Journal of experimental medicine · 1992Article
- Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.Antimicrobial agents and chemotherapy · 1992Review
- Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.Journal of virology · 1992Article
- Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction.The Journal of clinical investigation · 1991Article
- Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.Proceedings of the National Academy of Sciences of the United States of America · 1991Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We tried to assess the long-term safety and potential efficacy of passive immunization in AIDS-related-complex (ARC) and AIDS patients. We also wanted to establish whether hyperimmune plasma from healthy human immunodeficiency virus 1 (HIV-1)-infected individuals clears the cell-free virus from circulation. Using the polymerase chain reaction (PCR), we were able to provide conclusive evidence that hyperimmune plasma is effective and maintains long-term neutralization of viremia. Using the cell test, we found that in most patients the total antibody level was maintained; in one of the ARC patients, it actually increased 8-fold and has remained at that level for nearly 2 years. The CD4+ cell count decreased in the AIDS patients but was stable in the ARC patient. Clinically, there was an initial improvement in all patients, but five of six of the advanced/terminal AIDS patients had died by month 17. Our studies suggest that passive immunization may be safe in ARC and AIDS patients. It reduces HIV-1 viremia to levels undetectable even by PCR. To advanced/terminal patients, the benefit is of limited duration, while to ARC patients it may be long-term. Therefore, passive immunization should start early in the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.